Souhaitez-vous accéder aux communiqués récents ?

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial...

BOSTON and OAK BROOK, Ill. and SACRAMENTO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- After rigorous deliberation, Eleos, the leader in AI for behavioral health, today announced that the California...

BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the...

Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT™) with its innovative RadioGel® technology, today...

Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or...

Philanthropic funding from the FA Alliance Innovation Fund was awarded to five Oxford researchers to support the development of novel therapeutics

PORTLAND, Ore., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug...

Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio,...

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for...